Vasculotide 是一种可穿透血脑屏障 (BBB) 的 Tie2 激活剂,它可结合 Tie2 的一个独特结构域,使受体聚集以驱动磷酸化,激活下游 PI3K/Akt、eNOS 通路并增强内皮细胞间连接 (VE-cadherin、claudin-5 等),抑制炎症黏附分子,最终稳定血管内皮屏障、降低通透性,同时可减轻体外循环致肺微血管渗漏与微循环障碍、作为放疗辅助保护剂减轻急性放射性皮炎、促进聚焦超声 (FUS) 后 BBB 恢复,并与抗生素联用减轻肺损伤。
产品编号: MS-B01366 纯度: 99.84% CAS No.: 1359657-45-6
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Vasculotide 是一种可穿透血脑屏障 (BBB) 的 Tie2 激活剂,它可结合 Tie2 的一个独特结构域,使受体聚集以驱动磷酸化,激活下游 PI3K/Akt、eNOS 通路并增强内皮细胞间连接 (VE-cadherin、claudin-5 等),抑制炎症黏附分子,最终稳定血管内皮屏障、降低通透性,同时可减轻体外循环致肺微血管渗漏与微循环障碍、作为放疗辅助保护剂减轻急性放射性皮炎、促进聚焦超声 (FUS) 后 BBB 恢复,并与抗生素联用减轻肺损伤。

生物实验数据

生物活性 Vasculotide is a blood-brain barrier (BBB)-penetrating Tie2 activator that binds to a unique domain of Tie2, inducing receptor clustering to drive phosphorylation, activating downstream PI3K/Akt and eNOS pathways, enhancing interendothelial junctions (VE-cadherin, claudin-5, etc.), and inhibiting inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing permeability, while also alleviating cardiopulmonary bypass-induced pulmonary microvascular leakage and microcirculatory disturbance, serving as a radiotherapeutic adjuvant protective agent to reduce acute radiation dermatitis, promoting BBB recovery after focused ultrasound (FUS), and attenuating lung injury in combination with antibiotics.
体外研究
(In Vitro)

Vasculotide (28 ng/mL; 3 h) 可提高受辐照 HMVEChTERT 细胞的克隆形成存活率,其显著的 SER 值为 1.17。
Vasculotide (28 ng/mL; 3 h) 可保留经 4 Gy 辐照的 HMVEChTERTs 的血管生成能力,使其形成的小管与未辐照细胞相当。
Vasculotide (15 min) 可刺激 HMVEChTERTs 中 Tie2 受体的磷酸化,并激活下游 AKT 促存活通路。

体内研究
(In Vivo)

Vasculotide (200 ng/只;静脉注射;单剂量) 可在心肺转流术期间及术后保留雄性 Wistar 大鼠的微循环灌注,并减少其肺血管渗漏,且不会改变内源性血管生成素/Tie2 系统。
Vasculotide (10 μg/kg;腹腔注射;照射前 24 h 和 1.5 h 给药,之后每隔 1 天给药 1 次,持续 28 天) 可减轻小鼠急性皮肤辐射损伤,具体表现为重度脱屑伤口总面积减少 43%、炎症反应减轻以及伤口愈合情况改善。
Vasculotide (10 μg/kg;腹腔注射;仅照射前、持续给药、仅照射后;共 26 天) 经所有受试给药方案 (照射前、持续给药、照射后) 给药后,可减轻接受 35 Gy 照射小鼠的急性皮肤辐射损伤,其中照射后给药方案可使总体皮肤损伤评分显著降低 28%。
Vasculotide (250 ng;腹腔注射;每 48 小时 1 次;持续 3 个月) 可使 TgCRND8 小鼠中聚焦超声 (FUS) 诱导血脑屏障 (BBB) 通透性的超谐波阈值压力降低 21-29%,并加速 BBB 修复,在该阿尔茨海默病模型中,FUS 处理后 20 小时 BBB 闭合率可达 87%。
Vasculotide (500 ng;静脉注射;2 次给药) 联合 Ampicillin (MS-V19309) 的辅助治疗可显著降低机械通气肺炎链球菌肺炎小鼠的肺通透性、呼吸机相关性肺损伤 (VILI) 相关组织学损伤及水肿形成,且不影响免疫应答或细菌载量。

Animal Model: Wistar (male, 375-425 g)
Dosage: 200 ng
Administration: i.v.; single dose
Result: Completely preserved microcirculatory perfusion during and after CPB, with the number of continuously perfused and non-perfused vessels remaining stable throughout the experiment.
Significantly reduced Evans blue dye extravasation in lung tissue compared with untreated CPB rats.
Did not significantly reduce leakage in kidney tissue.
Did not affect circulating concentrations of angiopoietin-1, angiopoietin-2, or soluble Tie2.
Did not affect angiopoietin-1, angiopoietin-2, or Tie2 gene/protein expression in kidney or lung tissue, or endothelial adhesion molecule expression compared with untreated CPB rats.
Animal Model: athymic nude mice (7-week-old female)
Dosage: 10 μg/kg
Administration: i.p.; 24 h and 1.5 h before irradiation, then every other day; 28 days
Result: Reduced skin damage scores on day 6 and day 8, with no significant difference in overall area under the curve.
Reduced mean severe desquamation wound area overall, with peak areas reduced on day 12 and day 14.
Reduced weight loss 2 days post-irradiation, with full weight recovery by day 28.
Lowered oxygenated hemoglobin (oxyHb) levels overall, with trends toward lower levels on day 5, day 9, and day 12.
Reduced myeloperoxidase bioluminescence signal 6.4-fold lower than PBS at 72 h post-irradiation, and reduced neutrophil counts in skin sections on day 5.
Reduced serum MIP-2/CXCL2 levels on day 5 post-irradiation.
Increased CD31+ microvascular endothelial cell staining-to-area ratio on day 14 post-irradiation, with no significant difference in CD45+ leukocyte staining.
Reduced ulcerated wounds by day 28 post-irradiation (1 of 5 vs. 4 of 5 in PBS group), with histological evidence of better healing.
Animal Model: athymic nude mice (7-week-old female)
Dosage: 10 μg/kg
Administration: i.p.; pre-irradiation only (24 h and 1.5 h before irradiation); continuous (24 h and 1.5 h before irradiation, then every other day); post-irradiation only (starting 2 days after irradiation, then every other day); 26 days
Result: Reduced overall skin damage scores with post-irradiation treatment, with higher body weight by day 26 and significantly reduced myeloperoxidase bioluminescence on day 23 post-irradiation.
Reduced total wound size overall with pre-irradiation, continuous, and post-irradiation treatments.
Animal Model: Mixed C57/C3H background (male and female, 3 months old at study start; transgenic TgCRND8 with double amyloid precursor protein mutations KM670/671NL, V717F; non-transgenic littermate controls)
Dosage: 250 ng
Administration: i.p.; every 48 hours; 3 months
Result: Reduced the ultra-harmonic threshold pressure for FUS-induced BBB permeability by 21-29% compared to all other groups.
Did not alter initial gadolinium enhancement post-FUS in either TgCRND8 or non-transgenic mice.
Accelerated BBB closure in TgCRND8 mice: at 6, 12, and 20 hours post-FUS, 26%, 17%, and 13% of focal spots remained permeable to gadolinium, respectively, leading to 87% BBB closure by 20 hours.
Resulted in 61%, 26%, and 26% of focal spots remaining permeable to gadolinium at 6, 12, and 20 hours post-FUS in non-transgenic mice, respectively, leading to 74% BBB closure by 20 hours.
Showed a statistically significant difference in BBB closure rate between Vasculotide-treated and PBS-treated TgCRND8 mice via log-rank analysis.
Led to no detectable Evans blue dye in the brain at 24 hours post-FUS in both Vasculotide-treated TgCRND8 and non-transgenic mice, indicating complete BBB impermeability.
Animal Model: C57BL/6N (female, 8-10 weeks old, 18-20 g, intranasal inoculation with 5 × 106 CFU Streptococcus pneumoniae serotype 3 followed by 6 hours of mechanical ventilation starting 24 hours post-infection)
Dosage: 500 ng (first dose); 500 ng (second dose)
Administration: i.v.; 2 doses (22 hours post-infection, 1.5 hours prior to experiment termination)
Result: Significantly reduced pulmonary hyperpermeability (measured as HSA BALF/plasma ratio) compared to ampicillin monotherapy.
Reduced the percentage of lung area affected by VILI compared to ampicillin monotherapy or untreated mice.
Reduced VILI severity scores compared to ampicillin monotherapy or untreated mice.
Diminished alveolar edema formation in VILI-affected lung areas compared to ampicillin monotherapy or untreated mice.
Reduced perivascular edema formation in pneumonia-affected lung areas compared to ampicillin monotherapy or untreated mice.
Did not alter pulmonary or systemic leukocyte counts, cytokine/chemokine production, local or systemic bacterial burden, pulmonary Tie2 mRNA expression, or pulmonary Tie2 phosphorylation.
性状 固体
颜色 White to off-white

化学信息

CAS No. 1359657-45-6

储存&溶解度

储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础